ReviewThe Prostate2020
Disparities in prostate cancer incidence and mortality rates: Solvable or not?
Review in The Prostate, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.BMC cancer · 2025Pooled it
- Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO clinical cancer informatics · 2025Trial
- Association Between Dietary Folate and Prostate Cancer Aggressiveness Among African Americans and European Americans.Nutrients · 2026Article
- RAD51-AS1 inhibits the migration and invasion of prostate cancer cells by up-regulating RARA to activate ZYX transcription.Discover oncology · 2025Article
- Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients.Cancer research communications · 2025Article
- Socioeconomic and Geographic Disparities in Anorectal and Urinary Procedures Following Radiotherapy for Prostate Cancer.Cancer medicine · 2025Article
- Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis.Discover oncology · 2025Review
- Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria.JCO global oncology · 2025Article
- Predictors of late diagnosis of prostate cancer among men of African ancestry receiving care at urology clinic, Federal Medical Centre, Abeokuta.Ecancermedicalscience · 2025Article
- The global, regional, and national prostate cancer burden and trends from 1990 to 2021, results from the global burden of disease study 2021.Frontiers in public health · 2025Article
- The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area.Annals of surgical oncology · 2024Article
- Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT.Scientific reports · 2024Article
- Prognostic Nomogram Predicting Survival and Propensity Score Matching with Demographics and Comparative Analysis of Prostate Small Cell and Large Cell Neuroendocrine Carcinoma.Journal of clinical medicine · 2024Article
- Derivation of human primary prostate epithelial cell lines by differentially targeting theResearch square · 2024Article
- Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019.International urology and nephrology · 2023Article
- Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.JCO oncology practice · 2023Article
- Regulatory Role of Fatty Acid Metabolism-Related Long Noncoding RNA in Prostate Cancer: A Computational Biology Study Analysis.Journal of oncology · 2023Article
- Social ecological influences on treatment decision-making in men diagnosed with low risk, localised prostate cancer.European journal of cancer care · 2022Article
- Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.Cancer research communications · 2022Article
- An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean.Lancet regional health. Americas · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Prostate cancer (PCa) is recognized as a disease possessing not only great variation in its geographic and racial distribution but also tremendous variation in its potential to cause morbidity and death and it, therefore, ought not to be considered a homogenous disease entity. Morbidity and death from PCa are disproportionately higher in men of African ancestry (MAA) who are generally observed to have more aggressive disease and worse outcomes following treatment compared to men of European ancestry (MEA). The higher rates of PCa among MAA relative to MEA appear to be multifactorial and related to inherent differences in biological aggressiveness; a continued lack of awareness of the disease and methods of prevention; a lower prevalence of screen-detected PCa; comparatively lower access to quality healthcare as well as systemic and institutionalized disparities in the administration of optimal care to MAA in developed countries such as the United States of America where high-quality care is available. Even when access to quality healthcare is assured in equal access settings, it appears that MAA still have worse outcomes after PCa treatment stage-for-stage and grade-for-grade compared to MEA, suggesting that, inherent racial, ethnic and biological differences are paramount in predicting poor outcomes. This review has explored the different contributing factors to the current disparities in PCa incidence and mortality rates with emphasis on the incongruence in how research has been conducted in understanding the disease towards developing therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.